We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant.
- Authors
Le Bourgeois, Amandine; Coste‐Burel, Marianne; Guillaume, Thierry; Peterlin, Pierre; Garnier, Alice; Imbert, Berthe‐Marie; Drumel, Thomas; Mahé, Beatrice; Dubruille, Viviane; Blin, Nicolas; Lok, Anne; Touzeau, Cyrille; Gastinne, Thomas; Tessoulin, Benoît; Jullien, Maxime; Vantyghem, Sophie; Moreau, Philippe; Le Gouill, Steven; Béné, Marie C.; Chevallier, Patrice
- Abstract
Finally, the proportion of patients documented twice with the highest antibody level at SpV2 and SpV2+/SpV3 was similar between V3- and V3+ patients (50% vs. 60%, I P i = 0-55). Vaccine, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA, coronavirus disease 2019 (COVID-19), allogeneic haematopoietic stem cell transplantation, BNT162b2, third dose Keywords: coronavirus disease 2019 (COVID-19); vaccine; allogeneic haematopoietic stem cell transplantation; BNT162b2; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA; third dose EN coronavirus disease 2019 (COVID-19) vaccine allogeneic haematopoietic stem cell transplantation BNT162b2 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA third dose e38 e40 3 02/28/22 20220301 NES 220301 The efficacy of two doses of anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) messenger RNA (mRNA) vaccines, successfully demonstrated in healthy populations,1 is progressively reported in recipients of allogeneic haematopoietic stem cell transplant (allo-HSCT) with, surprisingly, high humoral antibody responses of ~80%.1-3 In our own experience based on an observational study of 117 allo-HSCT adult recipients, we found that 83% of them achieved a significant specific humoral response after two doses (V1 and V2) of BNT162b2 anti-SARS-CoV-2 mRNA vaccine (Pfizer BioNTech).
- Subjects
STEM cell transplantation; TRANSPLANTATION of organs, tissues, etc.; MESSENGER RNA; COVID-19 vaccines; SARS-CoV-2; HEMATOPOIETIC stem cell transplantation; SARS-CoV-2 Delta variant
- Publication
British Journal of Haematology, 2022, Vol 196, Issue 5, pe38
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17911